person · Reporting owner

EVNIN LUKE

Disclosed activity across 13 companies

Tapewire entity: 2480
SEC CIK: 0001134657

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aktis Oncology, Inc.AKTS · Entity 4711	10% owner	January 12, 2026	January 14, 2026
Dyne Therapeutics, Inc.DYN · Entity 3948	10% owner	September 21, 2020	September 23, 2020
Oncorus, Inc.ONCR · Entity 112213	Director	June 23, 2022	June 24, 2022
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693	10% owner	October 10, 2017	October 11, 2017
Syndax Pharmaceuticals IncSNDX · Entity 4578	Director · 10% owner	May 23, 2018	May 25, 2018
TURMERIC ACQUISITION CORP.TMPM · Entity 139875	Chief Executive Officer	April 30, 2021	April 30, 2021
Werewolf Therapeutics, Inc.HOWL · Entity 7244	Director	July 06, 2026	July 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aktis Oncology, Inc.

Report date January 12, 2026 · Filed January 14, 2026

Jointly reported with MPM BIOVENTURES 2018, L.P., MPM BIOVENTURES 2018 (B), L.P., MPM BioVentures 2018 LLC, MPM BioVentures 2018 GP LLC, MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, MPM ONCOLOGY INNOVATIONS FUND LP, MPM Oncology Innovations Fund GP LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,655,971	Reported balance After 2026-01-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-01-12 · Conversion · Acquired 1,314,262 · Balance 1,655,971 F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,570,168	Reported balance After 2026-01-12 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-01-12 · Conversion · Acquired 5,914,197 · Balance 7,570,168 F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	9,147,287	Reported balance After 2026-01-12 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-01-12 · Conversion · Acquired 1,577,119 · Balance 9,147,287 F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	10,260,064	Reported balance After 2026-01-12 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-01-12 · Purchase · Acquired 1,112,777 · Balance 10,260,064 F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F10: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.
Series Seed Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-12 · Conversion · Disposed 5,000,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-12 · Conversion · Disposed 22,500,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-12 · Conversion · Disposed 6,000,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact.

F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.

F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F4: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.

F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.

F6: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.

F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.

F8: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.

F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact.

F10: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.

Dyne Therapeutics, Inc.

Report date September 21, 2020 · Filed September 23, 2020

Jointly reported with MPM BIOVENTURES 2018, L.P., MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, MPM BioVentures 2018 GP LLC, MPM BioVentures 2018 LLC, Foley Todd, GADICKE ANSBERT

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,614,943	Reported balance After 2020-09-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-09-21 · Conversion · Acquired 4,614,943 · Balance 4,614,943 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	245,279	Reported balance After 2020-09-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-09-21 · Conversion · Acquired 245,279 · Balance 245,279 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	91,081	Reported balance After 2020-09-21 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-09-21 · Conversion · Acquired 91,081 · Balance 91,081 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-09-21 · Conversion · Disposed 13,980,992 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-09-21 · Conversion · Disposed 743,076 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-09-21 · Conversion · Disposed 275,932 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-09-21 · Conversion · Disposed 1,326,313 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-09-21 · Conversion · Disposed 70,492 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-09-21 · Conversion · Disposed 26,176 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.

F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.

F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.

F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Oncorus, Inc.

Report date June 23, 2022 · Filed June 24, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2032-06-23	Direct	12,500	Reported balance After 2022-06-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-23 · Grant · Acquired 12,500 · Balance 12,500 F1: The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date.

RHYTHM PHARMACEUTICALS, INC.

Report date October 10, 2017 · Filed October 11, 2017

Jointly reported with MPM BIOVENTURES V, L.P., GADICKE ANSBERT, MPM ASSET MANAGEMENT INVESTORS BV5 LLC, MPM BIOVENTURES V GP LLC, MPM BIOVENTURES V LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,596,392	Reported balance After 2017-10-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-10-10 · Conversion · Acquired 2,567,014 · Balance 2,596,392 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F2: The shares are held as follows: 2,499,299 by MPM BioVentures V, L.P. ("BV V") and 97,093 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,696,392	Reported balance After 2017-10-10 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2017-10-10 · Purchase · Acquired 100,000 · Balance 2,696,392 F3: Shares were purchased as follows: 96,260 by BV V and 3,740 by AM BV5. F4: Shares are held as follows: 2,595,559 by BV V and 100,833 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-10-10 · Conversion · Disposed 7,651,831 · Balance 0 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F5: The shares of Series A Preferred Stock were held as follows: 7,365,688 by BV V and 286,143 by AM BV5.
Series A-1 Junior Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-10-10 · Conversion · Disposed 15,887,703 · Balance 0 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F6: The shares of Series A-1 Junior Preferred Stock were held as follows: 15,293,569 by BV V and 594,134 by AM BV5.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date.

F2: The shares are held as follows: 2,499,299 by MPM BioVentures V, L.P. ("BV V") and 97,093 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F3: Shares were purchased as follows: 96,260 by BV V and 3,740 by AM BV5.

F4: Shares are held as follows: 2,595,559 by BV V and 100,833 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F5: The shares of Series A Preferred Stock were held as follows: 7,365,688 by BV V and 286,143 by AM BV5.

F6: The shares of Series A-1 Junior Preferred Stock were held as follows: 15,293,569 by BV V and 594,134 by AM BV5.

Syndax Pharmaceuticals Inc

Report date May 23, 2018 · Filed May 25, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.93 · Expires 2028-05-23	Direct	14,000	Reported balance After 2018-05-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-05-23 · Grant · Acquired 14,000 · Balance 14,000

TURMERIC ACQUISITION CORP.

Report date April 30, 2021 · Filed April 30, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	IndirectBy Turmeric Management, LLC	2,298,750	Reported balance After 2021-04-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-04-30 · Other · Acquired 17,500 · Balance 2,298,750 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. F2: Pursuant to certain repurchase agreement, dated as of April 30, 2021, 17,500 Class B ordinary shares of the Issuer were transferred from the Vinay Bhaskar to Turmeric Management, LLC as a result of Dr. Bhaskar's resignation as an officer of the Issuer. F3: The securities reported herein are held by Turmeric Management, LLC (the "Sponsor"). The Sponsor is governed by a board of directors consisting of one director, the Reporting Person. As such, the Reporting Person has voting and investment discretion with respect to the Class B ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class B ordinary shares held directly by the Sponsor.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

F2: Pursuant to certain repurchase agreement, dated as of April 30, 2021, 17,500 Class B ordinary shares of the Issuer were transferred from the Vinay Bhaskar to Turmeric Management, LLC as a result of Dr. Bhaskar's resignation as an officer of the Issuer.

F3: The securities reported herein are held by Turmeric Management, LLC (the "Sponsor"). The Sponsor is governed by a board of directors consisting of one director, the Reporting Person. As such, the Reporting Person has voting and investment discretion with respect to the Class B ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class B ordinary shares held directly by the Sponsor.

Werewolf Therapeutics, Inc.

Report date July 06, 2026 · Filed July 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	107,429	Reported balance After 2026-07-06 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-07-06 · Sale · Disposed 35,770 · Balance 107,429 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026. F2: The shares were sold as follows: 3,832 by MPM Asset Management LLC ("AM LLC"), 24,197 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,614 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 833 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,294 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3128 to $0.3388 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5: The shares are held as follows: 11,509 by AM LLC, 72,676 by BV 2014, 4,845 by BV 2014(B), 2,499 by AM BV2014 and 15,900 by MPM OIF.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	0	Reported balance After 2026-07-07 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-07-07 · Sale · Disposed 107,429 · Balance 0 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026. F6: The shares were sold as follows: 11,509 by AM LLC, 72,676 by BV 2014, 4,845 by BV 2014(B), 2,499 by AM BV2014 and 15,900 by MPM OIF. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.295 to $0.3342 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8: No shares held by AM LLC, BV 2014, BV 2014(B), AM BV2014 and MPM OIF.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.

F2: The shares were sold as follows: 3,832 by MPM Asset Management LLC ("AM LLC"), 24,197 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,614 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 833 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,294 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3128 to $0.3388 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F5: The shares are held as follows: 11,509 by AM LLC, 72,676 by BV 2014, 4,845 by BV 2014(B), 2,499 by AM BV2014 and 15,900 by MPM OIF.

F6: The shares were sold as follows: 11,509 by AM LLC, 72,676 by BV 2014, 4,845 by BV 2014(B), 2,499 by AM BV2014 and 15,900 by MPM OIF.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.295 to $0.3342 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: No shares held by AM LLC, BV 2014, BV 2014(B), AM BV2014 and MPM OIF.

Past disclosures · reporting ended (6)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Entrada Therapeutics, Inc.

Report date September 04, 2026 · Filed September 09, 2026

Jointly reported with MPM BioVentures 2014, L.P., GADICKE ANSBERT, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC

Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,106,452	Reported balance After 2026-09-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-09-04 · Sale · Disposed 38,500 · Balance 4,106,452 F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,913,952	Reported balance After 2026-09-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-09-08 · Sale · Disposed 192,500 · Balance 3,913,952 F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018. F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,885,115	Reported balance After 2026-09-09 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-09-09 · Sale · Disposed 28,837 · Balance 3,885,115 F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018. F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.

F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.

F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.

F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.

F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

Harpoon Therapeutics, Inc.

Report date April 15, 2021 · Filed April 16, 2021

Jointly reported with MPM BioVentures 2014, L.P., MPM ASSET MANAGEMENT LLC, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, Foley Todd

Section 16 reporting ended · disclosed 2021-04-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,223,853	Reported balance After 2021-04-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-04-13 · Sale · Disposed 1,657 · Balance 3,223,853 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold by MPM Asset Management LLC ("AM LLC"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.98 to $19.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 317,910 by AM LLC. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Messrs. Evnin and Foley are the members of BV LLC and Mr. Evnin is a member of AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,223,567	Reported balance After 2021-04-13 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-04-13 · Sale · Disposed 286 · Balance 3,223,567 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold by MPM Asset Management LLC ("AM LLC"). F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.89 to $20.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 317,624 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,223,446	Reported balance After 2021-04-14 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-04-14 · Sale · Disposed 121 · Balance 3,223,446 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold by MPM Asset Management LLC ("AM LLC"). F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.44 to $20.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 317,503 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,221,896	Reported balance After 2021-04-14 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-04-14 · Sale · Disposed 1,550 · Balance 3,221,896 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold by MPM Asset Management LLC ("AM LLC"). F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 315,953 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,220,844	Reported balance After 2021-04-15 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2021-04-15 · Sale · Disposed 1,052 · Balance 3,220,844 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold by MPM Asset Management LLC ("AM LLC"). F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 314,901 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.

F2: The shares were sold by MPM Asset Management LLC ("AM LLC").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.98 to $19.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 317,910 by AM LLC. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Messrs. Evnin and Foley are the members of BV LLC and Mr. Evnin is a member of AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.89 to $20.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 317,624 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.44 to $20.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 317,503 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 315,953 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 314,901 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Radius Health, Inc.

Report date September 27, 2016 · Filed September 29, 2016

Section 16 reporting ended · disclosed 2016-09-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,887,502	Reported balance After 2016-09-27 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2016-09-27 · Other · Disposed 1,943,751 · Balance 3,887,502 F1: Represents pro-rata in-kind distributions of Common Stock of the Issuer by MPM Bioventures III-QP, L.P. ("BV III QP"), MPM BioVentures III, L.P ("BV III"), MPM Asset Management Investors 2003 BVIII LLC ("AM 2003"), MPM BioVentures III Parallel Fund, L.P. ("BV Parallel"), MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG") and MPM Bio IV NVS Strategic Fund, L.P. ("MPM NVS"), without consideration to their respective limited partners and members. F2: The shares were distributed as follows: 1,023,819 shares by BV III QP, 68,835 shares by BV III, 19,815 shares by AM 2003, 30,911 shares by BV Parallel, 86,522 shares by BV KG and 713,849 shares by MPM NVS. F3: The shares are held as follows: 2,047,635 shares by BV III QP, 137,671 shares by BV III, 39,630 shares by AM 2003, 61,823 shares by BV Parallel, 173,045 shares by BV KG and 1,427,698 shares by MPM NVS. F4: MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III, BV Parallel and BV KG. The reporting person is a member of MPM III LLC and AM 2003. MPM BioVentures IV GP LLC ("BV IV GP LLC") and MPM BioVentures IV LLC ("BV IV LLC") are the direct and indirect general partners of MPM NVS. The reporting person is a member of BV IV LLC. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents pro-rata in-kind distributions of Common Stock of the Issuer by MPM Bioventures III-QP, L.P. ("BV III QP"), MPM BioVentures III, L.P ("BV III"), MPM Asset Management Investors 2003 BVIII LLC ("AM 2003"), MPM BioVentures III Parallel Fund, L.P. ("BV Parallel"), MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG") and MPM Bio IV NVS Strategic Fund, L.P. ("MPM NVS"), without consideration to their respective limited partners and members.

F2: The shares were distributed as follows: 1,023,819 shares by BV III QP, 68,835 shares by BV III, 19,815 shares by AM 2003, 30,911 shares by BV Parallel, 86,522 shares by BV KG and 713,849 shares by MPM NVS.

F3: The shares are held as follows: 2,047,635 shares by BV III QP, 137,671 shares by BV III, 39,630 shares by AM 2003, 61,823 shares by BV Parallel, 173,045 shares by BV KG and 1,427,698 shares by MPM NVS.

F4: MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III, BV Parallel and BV KG. The reporting person is a member of MPM III LLC and AM 2003. MPM BioVentures IV GP LLC ("BV IV GP LLC") and MPM BioVentures IV LLC ("BV IV LLC") are the direct and indirect general partners of MPM NVS. The reporting person is a member of BV IV LLC. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Repare Therapeutics Inc.

Report date June 23, 2020 · Filed June 25, 2020

Jointly reported with MPM BioVentures 2014, L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 (B), L.P., MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC

Section 16 reporting ended · disclosed 2020-06-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	1,801,581	Reported balance After 2020-06-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-06-23 · Conversion · Acquired 1,801,581 · Balance 1,801,581 F1: All series of convertible preferred shares converted into the number of shares of the Issuer's common shares on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2: The shares are held as follows: 1,636,136 by MPM BioVentures 2014, L.P. ("BV 2014"), 109,128 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 56,317 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC and members of AM BV2014. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	2,753,772	Reported balance After 2020-06-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-06-23 · Conversion · Acquired 952,191 · Balance 2,753,772 F1: All series of convertible preferred shares converted into the number of shares of the Issuer's common shares on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F4: The shares are held as follows: 2,500,885 by BV 2014, 166,805 by BV 2014(B) and 86,082 by AM BV2014.
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,003,772	Reported balance After 2020-06-23 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-06-23 · Purchase · Acquired 250,000 · Balance 3,003,772 F5: The shares were purchased as follows: 227,042 by BV 2014, 15,143 by BV 2014(B) and 7,815 by AM BV2014. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F6: The shares are held as follows: 2,727,927 by BV 2014, 181,948 by BV 2014(B) and 93,897 by AM BV2014.
Class A Preferred SharesSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2020-06-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-06-23 · Conversion · Disposed 1,801,581 · Balance 0 F1: All series of convertible preferred shares converted into the number of shares of the Issuer's common shares on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F7: No securities held by the Reporting Persons.
Class B Preferred SharesSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2020-06-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-06-23 · Conversion · Disposed 952,191 · Balance 0 F1: All series of convertible preferred shares converted into the number of shares of the Issuer's common shares on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F7: No securities held by the Reporting Persons.

Filing footnotes · ownership attribution and instrument terms

F1: All series of convertible preferred shares converted into the number of shares of the Issuer's common shares on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and had no expiration date.

F2: The shares are held as follows: 1,636,136 by MPM BioVentures 2014, L.P. ("BV 2014"), 109,128 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 56,317 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC and members of AM BV2014.

F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F4: The shares are held as follows: 2,500,885 by BV 2014, 166,805 by BV 2014(B) and 86,082 by AM BV2014.

F5: The shares were purchased as follows: 227,042 by BV 2014, 15,143 by BV 2014(B) and 7,815 by AM BV2014.

F6: The shares are held as follows: 2,727,927 by BV 2014, 181,948 by BV 2014(B) and 93,897 by AM BV2014.

F7: No securities held by the Reporting Persons.

TCR2 THERAPEUTICS INC.

Report date June 01, 2023 · Filed June 05, 2023

Jointly reported with MPM BioVentures 2014, L.P., Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM ASSET MANAGEMENT LLC

Section 16 reporting ended · disclosed 2023-06-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2023-06-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-06-01 · Other · Disposed 4,158,964 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 304,001 by MPM Asset Management LLC ("AM LLC"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Ansbert Gadicke is a member of SunStates GP and Luke Evnin and Anbsert Gadicke are the members of AM LLC.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").

F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 304,001 by MPM Asset Management LLC ("AM LLC"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Ansbert Gadicke is a member of SunStates GP and Luke Evnin and Anbsert Gadicke are the members of AM LLC.

iTeos Therapeutics, Inc.

Report date May 13, 2025 · Filed May 15, 2025

Jointly reported with MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 GP LLC, MPM BioVentures 2014 LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, Foley Todd

Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,108,594	Reported balance After 2025-05-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-05-13 · Sale · Disposed 630,191 · Balance 2,108,594 F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B) and 14,831 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B) and 14,831 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 12, 2026 Filed Jan 14, 2026 23:19 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionSeries A Redeemable Convertible Preferred Stock · Derivative	22,500,000	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000057 · form4-01142026_110117.xml · derivative · entry 6 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 5,914,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5 · ownership.nature: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:19 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionSeries Seed Redeemable Convertible Preferred Stock · Derivative	5,000,000	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000057 · form4-01142026_110117.xml · derivative · entry 5 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,314,262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F1 · ownership.nature: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:19 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	PurchaseCommon Stock	1,112,777	$18.00	$20,029,986.00	Disclosure SEC source: 0001231919-26-000057 · form4-01142026_110117.xml · nonDerivative · entry 4 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 10,260,064 F9 · shares: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F10 · ownership.nature: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:19 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionCommon Stock	1,577,119	Not disclosed	Not disclosed	Disclosure SEC source: 0001231919-26-000057 · form4-01142026_110117.xml · nonDerivative · entry 3 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 9,147,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:19 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionCommon Stock	5,914,197	Not disclosed	Not disclosed	Disclosure SEC source: 0001231919-26-000057 · form4-01142026_110117.xml · nonDerivative · entry 2 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 7,570,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6 · ownership.nature: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact. Read SEC document
January 12, 2026 Filed Jan 14, 2026 23:19 UTC	Aktis Oncology, Inc. AKTS · Entity 4711	ConversionCommon Stock	1,314,262	Not disclosed	Not disclosed	Disclosure SEC source: 0001231919-26-000057 · form4-01142026_110117.xml · nonDerivative · entry 1 MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner MPM ONCOLOGY INNOVATIONS FUND LP · CIK 0001719960 · 10% owner MPM Oncology Innovations Fund GP LLC · CIK 0001857903 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,655,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F2 · price: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4 · ownership.nature: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM. Read SEC document
January 09, 2026 Filed Jan 12, 2026 22:09 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	24,678	$0.61	$15,053.58	Disclosure SEC source: 0001134657-26-000004 · form4-01122026_100138.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,368,849 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 2,640 by AM LLC, 16,678 by BV 2014, 1,112 by BV 2014(B), 575 by AM BV2014 and 3,673 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6019 to $0.6583 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 253,767 by AM LLC, 1,602,300 by BV 2014, 106,871 by BV 2014(B), 55,145 by AM BV2014 and 350,766 by MPM OIF. Read SEC document
January 08, 2026 Filed Jan 12, 2026 22:09 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	7,716	$0.63	$4,861.08	Disclosure SEC source: 0001134657-26-000004 · form4-01122026_100138.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,393,527 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 825 by MPM Asset Management LLC ("AM LLC"), 5,215 by MPM BioVentures 2014, L.P. ("BV 2014"), 348 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 180 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 1,148 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6243 to $0.6368 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 256,407 by AM LLC, 1,618,978 by BV 2014, 107,983 by BV 2014(B), 55,720 by AM BV2014 and 354,439 by MPM OIF. Read SEC document
January 07, 2026 Filed Jan 7, 2026 22:12 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	11,915	$0.64	$7,625.60	Disclosure SEC source: 0001134657-26-000002 · form4-01072026_100145.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,401,243 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 1,275 by AM LLC, 8,053 by BV 2014, 537 by BV 2014(B), 277 by AM BV2014 and 1,773 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6276 to $0.6598 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 257,232 by AM LLC, 1,624,193 by BV 2014, 108,331 by BV 2014(B), 55,900 by AM BV2014 and 355,587 by MPM OIF. Read SEC document
January 06, 2026 Filed Jan 7, 2026 22:12 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	40,761	$0.65	$26,494.65	Disclosure SEC source: 0001134657-26-000002 · form4-01072026_100145.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,413,158 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 4,361 by AM LLC, 27,548 by BV 2014, 1,837 by BV 2014(B), 948 by AM BV2014 and 6,067 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.6599 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 258,507 by AM LLC, 1,632,246 by BV 2014, 108,868 by BV 2014(B), 56,177 by AM BV2014 and 357,360 by MPM OIF. Read SEC document
January 05, 2026 Filed Jan 7, 2026 22:12 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	18,378	$0.64	$11,761.92	Disclosure SEC source: 0001134657-26-000002 · form4-01072026_100145.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,453,919 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 1,966 by MPM Asset Management LLC ("AM LLC"), 12,420 by MPM BioVentures 2014, L.P. ("BV 2014"), 828 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 429 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,735 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.63435 to $0.6549 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 262,868 by AM LLC, 1,659,794 by BV 2014, 110,705 by BV 2014(B), 57,125 by AM BV2014 and 363,427 by MPM OIF. Read SEC document
January 02, 2026 Filed Jan 2, 2026 22:32 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	18,568	$0.63	$11,697.84	Disclosure SEC source: 0001134657-26-000001 · form4-01022026_100128.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,472,297 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 1,986 by AM LLC, 12,549 by BV 2014, 837 by BV 2014(B), 432 by AM BV2014 and 2,764 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.6499 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 264,834 by AM LLC, 1,672,214 by BV 2014, 111,533 by BV 2014(B), 57,554 by AM BV2014 and 366,162 by MPM OIF. Read SEC document
December 31, 2025 Filed Jan 2, 2026 22:32 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	24,962	$0.62	$15,476.44	Disclosure SEC source: 0001134657-26-000001 · form4-01022026_100128.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,490,865 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 2,670 by AM LLC, 16,870 by BV 2014, 1,125 by BV 2014(B), 582 by AM BV2014 and 3,715 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6038 to $0.6359 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 266,820 by AM LLC, 1,684,763 by BV 2014, 112,370 by BV 2014(B), 57,986 by AM BV2014 and 368,926 by MPM OIF. Read SEC document
December 30, 2025 Filed Jan 2, 2026 22:32 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	34,847	$0.61	$21,256.67	Disclosure SEC source: 0001134657-26-000001 · form4-01022026_100128.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,515,827 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 3,728 by MPM Asset Management LLC ("AM LLC"), 23,551 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,571 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 811 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,186 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6085 to $0.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 269,490 by AM LLC, 1,701,633 by BV 2014, 113,495 by BV 2014(B), 58,568 by AM BV2014 and 372,641 by MPM OIF. Read SEC document
December 29, 2025 Filed Dec 29, 2025 22:27 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	108,606	$0.61	$66,249.66	Disclosure SEC source: 0001134657-25-000018 · form4-12292025_101245.xml · nonDerivative · entry 5 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,550,674 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F15 · shares: The shares were sold as follows: 11,618 by AM LLC, 73,401 by BV 2014, 4,896 by BV 2014(B), 2,526 by AM BV2014 and 16,165 by MPM OIF. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.58955 to $0.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F17 · ownership.nature: The shares are held as follows: 273,218 by AM LLC, 1,725,184 by BV 2014, 115,066 by BV 2014(B), 59,379 by AM BV2014 and 377,827 by MPM OIF. Read SEC document
December 26, 2025 Filed Dec 29, 2025 22:27 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	35,632	$0.63	$22,448.16	Disclosure SEC source: 0001134657-25-000018 · form4-12292025_101245.xml · nonDerivative · entry 4 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,659,280 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F12 · shares: The shares were sold as follows: 3,812 by AM LLC, 24,082 by BV 2014, 1,606 by BV 2014(B), 829 by AM BV2014 and 5,303 by MPM OIF. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6165 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F14 · ownership.nature: The shares are held as follows: 284,836 by AM LLC, 1,798,585 by BV 2014, 119,962 by BV 2014(B), 61,905 by AM BV2014 and 393,992 by MPM OIF. Read SEC document
December 24, 2025 Filed Dec 29, 2025 22:27 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	16,310	$0.65	$10,601.50	Disclosure SEC source: 0001134657-25-000018 · form4-12292025_101245.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,694,912 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 1,745 by AM LLC, 11,023 by BV 2014, 735 by BV 2014(B), 379 by AM BV2014 and 2,428 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6337 to $0.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 288,648 by AM LLC, 1,822,667 by BV 2014, 121,568 by BV 2014(B), 62,734 by AM BV2014 and 399,295 by MPM OIF. Read SEC document
December 23, 2025 Filed Dec 29, 2025 22:27 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	71,428	$0.63	$44,999.64	Disclosure SEC source: 0001134657-25-000018 · form4-12292025_101245.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,711,222 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 7,641 by AM LLC, 48,274 by BV 2014, 3,220 by BV 2014(B), 1,662 by AM BV2014 and 10,631 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.61 to $0.6728 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 290,393 by AM LLC, 1,833,690 by BV 2014, 122,303 by BV 2014(B), 63,113 by AM BV2014 and 401,723 by MPM OIF. Read SEC document
December 22, 2025 Filed Dec 29, 2025 22:27 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	59,307	$0.69	$40,921.83	Disclosure SEC source: 0001134657-25-000018 · form4-12292025_101245.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,782,650 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 6,344 by MPM Asset Management LLC ("AM LLC"), 40,082 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,673 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,381 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 8,827 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6596 to $0.7341 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 298,034 by AM LLC, 1,881,964 by BV 2014, 125,523 by BV 2014(B), 64,775 by AM BV2014 and 412,354 by MPM OIF. Read SEC document
December 17, 2025 Filed Dec 17, 2025 23:28 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	9,983	$1.14	$11,380.62	Disclosure SEC source: 0001134657-25-000017 · form4-12172025_111249.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,841,957 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 1,068 by AM LLC, 6,747 by BV 2014, 450 by BV 2014(B), 232 by AM BV2014 and 1,486 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.095 to $1.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 304,378 by AM LLC, 1,922,046 by BV 2014, 128,196 by BV 2014(B), 66,156 by AM BV2014 and 421,181 by MPM OIF. Read SEC document
December 16, 2025 Filed Dec 17, 2025 23:28 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	14,548	$1.05	$15,275.40	Disclosure SEC source: 0001134657-25-000017 · form4-12172025_111249.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,851,940 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 1,556 by AM LLC, 9,832 by BV 2014, 656 by BV 2014(B), 339 by AM BV2014 and 2,165 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 305,446 by AM LLC, 1,928,793 by BV 2014, 128,646 by BV 2014(B), 66,388 by AM BV2014 and 422,667 by MPM OIF. Read SEC document
December 15, 2025 Filed Dec 17, 2025 23:28 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	23,640	$1.07	$25,294.80	Disclosure SEC source: 0001134657-25-000017 · form4-12172025_111249.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,866,488 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 2,529 by MPM Asset Management LLC ("AM LLC"), 15,977 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,066 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 550 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 3,518 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 307,002 by AM LLC, 1,938,625 by BV 2014, 129,302 by BV 2014(B), 66,727 by AM BV2014 and 424,832 by MPM OIF. Read SEC document
December 12, 2025 Filed Dec 12, 2025 22:32 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	17,858	$1.08	$19,286.64	Disclosure SEC source: 0001134657-25-000016 · form4-12122025_101227.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,890,128 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 1,910 by AM LLC, 12,069 by BV 2014, 805 by BV 2014(B), 416 by AM BV2014 and 2,658 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.06 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 309,531 by AM LLC, 1,954,602 by BV 2014, 130,368 by BV 2014(B),67,277 by AM BV2014 and 428,350 by MPM OIF. Read SEC document
December 11, 2025 Filed Dec 12, 2025 22:32 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	28,009	$1.07	$29,969.63	Disclosure SEC source: 0001134657-25-000016 · form4-12122025_101227.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,907,986 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 2,996 by AM LLC, 18,930 by BV 2014, 1,263 by BV 2014(B), 651 by AM BV2014 and 4,169 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 311,441 by AM LLC, 1,966,671 by BV 2014, 131,173 by BV 2014(B), 67,693 by AM BV2014 and 431,008 by MPM OIF. Read SEC document
December 10, 2025 Filed Dec 12, 2025 22:32 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	37,104	$1.06	$39,330.24	Disclosure SEC source: 0001134657-25-000016 · form4-12122025_101227.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,935,995 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 3,969 by MPM Asset Management LLC ("AM LLC"), 25,077 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,673 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 863 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,522 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9742 to $1.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 314,437 by AM LLC, 1,985,601 by BV 2014, 132,436 by BV 2014(B), 68,344 by AM BV2014 and 435,177 by MPM OIF. Read SEC document
December 09, 2025 Filed Dec 9, 2025 22:07 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	44,570	$1.01	$45,015.70	Disclosure SEC source: 0001134657-25-000015 · form4-12092025_101231.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 2,973,099 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 4,768 by AM LLC, 30,123 by BV 2014, 2,009 by BV 2014(B), 1,036 by AM BV2014 and 6,634 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.99 to $1.025 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 318,406 by AM LLC, 2,010,678 by BV 2014, 134,109 by BV 2014(B), 69,207 by AM BV2014 and 440,699 by MPM OIF. Read SEC document
December 08, 2025 Filed Dec 9, 2025 22:07 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	34,041	$0.99	$33,700.59	Disclosure SEC source: 0001134657-25-000015 · form4-12092025_101231.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,017,669 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,642 by AM LLC, 23,006 by BV 2014, 1,534 by BV 2014(B), 792 by AM BV2014 and 5,067 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9582 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 323,174 by AM LLC, 2,040,801 by BV 2014, 136,118 by BV 2014(B), 70,243 by AM BV2014 and 447,333 by MPM OIF. Read SEC document
December 05, 2025 Filed Dec 9, 2025 22:07 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	16,568	$0.97	$16,070.96	Disclosure SEC source: 0001134657-25-000015 · form4-12092025_101231.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,051,710 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 1,772 by MPM Asset Management LLC ("AM LLC"), 11,197 by MPM BioVentures 2014, L.P. ("BV 2014"), 747 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 386 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,466 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9434 to $0.9863 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 326,816 by AM LLC, 2,063,807 by BV 2014, 137,652 by BV 2014(B), 71,035 by AM BV2014 and 452,400 by MPM OIF. Read SEC document
December 04, 2025 Filed Dec 4, 2025 23:20 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	53,416	$0.97	$51,813.52	Disclosure SEC source: 0001134657-25-000014 · form4-12042025_111226.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,068,278 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014 and 7,950 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014 and 454,866 by MPM OIF. Read SEC document
December 03, 2025 Filed Dec 4, 2025 23:20 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	36,726	$0.87	$31,951.62	Disclosure SEC source: 0001134657-25-000014 · form4-12042025_111226.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,121,694 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014 and 5,466 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014 and 462,816 by MPM OIF. Read SEC document
December 02, 2025 Filed Dec 4, 2025 23:20 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	38,043	$0.89	$33,858.27	Disclosure SEC source: 0001134657-25-000014 · form4-12042025_111226.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,158,420 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014 and 468,282 by MPM OIF. Read SEC document
December 01, 2025 Filed Dec 1, 2025 23:13 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	39,096	$0.94	$36,750.24	Disclosure SEC source: 0001134657-25-000013 · form4-12012025_111233.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,196,463 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 4,182 by AM LLC, 26,423 by BV 2014, 1,762 by BV 2014(B), 910 by AM BV2014 and 5,819 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.905 to $1.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 342,301 by AM LLC, 2,161,638 by BV 2014, 144,178 by BV 2014(B), 74,402 by AM BV2014 and 473,944 by MPM OIF. Read SEC document
November 28, 2025 Filed Dec 1, 2025 23:13 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	13,014	$0.99	$12,883.86	Disclosure SEC source: 0001134657-25-000013 · form4-12012025_111233.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,235,559 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 1,392 by AM LLC, 8,795 by BV 2014, 587 by BV 2014(B), 303 by AM BV2014 and 1,937 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9681 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 346,483 by AM LLC, 2,188,061 by BV 2014, 145,940 by BV 2014(B), 75,312 by AM BV2014 and 479,763 by MPM OIF. Read SEC document
November 26, 2025 Filed Dec 1, 2025 23:13 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	38,978	$0.98	$38,198.44	Disclosure SEC source: 0001134657-25-000013 · form4-12012025_111233.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,248,573 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,170 by MPM Asset Management LLC ("AM LLC"), 26,343 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,757 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 907 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,801 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 347,875 by AM LLC, 2,196,856 by BV 2014, 146,527 by BV 2014(B), 75,615 by AM BV2014 and 481,700 by MPM OIF. Read SEC document
November 25, 2025 Filed Nov 25, 2025 23:05 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	27,297	$0.92	$25,113.24	Disclosure SEC source: 0001134657-25-000012 · form4-11252025_111121.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,287,551 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 2,920 by AM LLC, 18,449 by BV 2014, 1,230 by BV 2014(B), 635 by AM BV2014 and 4,063 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 352,045 by AM LLC, 2,223,199 by BV 2014, 148,284 by BV 2014(B), 76,522 by AM BV2014 and 487,501 by MPM OIF. Read SEC document
November 24, 2025 Filed Nov 25, 2025 23:05 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	56,992	$0.98	$55,852.16	Disclosure SEC source: 0001134657-25-000012 · form4-11252025_111121.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,314,848 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 6,097 by AM LLC, 38,518 by BV 2014, 2,569 by BV 2014(B), 1,325 by AM BV2014 and 8,483 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8733 to $1.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 354,965 by AM LLC, 2,241,648 by BV 2014, 149,514 by BV 2014(B), 77,157 by AM BV2014 and 491,564 by MPM OIF. Read SEC document
November 21, 2025 Filed Nov 25, 2025 23:05 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	41,287	$0.83	$34,268.21	Disclosure SEC source: 0001134657-25-000012 · form4-11252025_111121.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,371,840 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,417 by MPM Asset Management LLC ("AM LLC"), 27,904 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,861 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 960 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 6,145 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.8861 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 361,062 by AM LLC, 2,280,166 by BV 2014, 152,083 by BV 2014(B), 78,482 by AM BV2014 and 500,047 by MPM OIF. Read SEC document
November 20, 2025 Filed Nov 20, 2025 22:52 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	26,411	$0.89	$23,505.79	Disclosure SEC source: 0001134657-25-000011 · form4-11202025_101135.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,413,127 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014 and 3,931 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014 and 506,192 by MPM OIF. Read SEC document
November 19, 2025 Filed Nov 20, 2025 22:52 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	42,566	$0.94	$40,012.04	Disclosure SEC source: 0001134657-25-000011 · form4-11202025_101135.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,439,538 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014 and 6,335 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014 and 510,123 by MPM OIF. Read SEC document
November 18, 2025 Filed Nov 20, 2025 22:52 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	33,776	$0.93	$31,411.68	Disclosure SEC source: 0001134657-25-000011 · form4-11202025_101135.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,482,104 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 3,613 by MPM Asset Management LLC ("AM LLC"), 22,827 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,523 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 786 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,027 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014 and 516,458 by MPM OIF. Read SEC document
November 17, 2025 Filed Nov 18, 2025 00:23 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	36,621	$0.95	$34,789.95	Disclosure SEC source: 0001134657-25-000010 · form4-11182025_121123.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,515,880 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 3,918 by AM LLC, 24,750 by BV 2014, 1,651 by BV 2014(B), 851 by AM BV2014 and 5,451 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9183 to $0.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 376,471 by AM LLC, 2,377,515 by BV 2014, 158,577 by BV 2014(B), 81,832 by AM BV2014 and 521,485 by MPM OIF. Read SEC document
November 14, 2025 Filed Nov 18, 2025 00:23 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	39,560	$0.93	$36,790.80	Disclosure SEC source: 0001134657-25-000010 · form4-11182025_121123.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,552,501 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 4,232 by AM LLC, 26,736 by BV 2014, 1,783 by BV 2014(B), 921 by AM BV2014 and 5,888 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.895 to $0.9551 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 380,389 by AM LLC, 2,402,265 by BV 2014, 160,228 by BV 2014(B), 82,683 by AM BV2014 and 526,936 by MPM OIF. Read SEC document
November 13, 2025 Filed Nov 18, 2025 00:23 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	58,372	$0.98	$57,204.56	Disclosure SEC source: 0001134657-25-000010 · form4-11182025_121123.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,592,061 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 6,244 by MPM Asset Management LLC ("AM LLC"), 39,450 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,631 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 8,688 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.918 to $1.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 384,621 by AM LLC, 2,429,001 by BV 2014, 162,011 by BV 2014(B), 83,604 by AM BV2014 and 532,824 by MPM OIF. Read SEC document
November 12, 2025 Filed Nov 13, 2025 00:49 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	26,101	$1.09	$28,450.09	Disclosure SEC source: 0001134657-25-000008 · form4-11132025_121129.xml · nonDerivative · entry 4 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,650,433 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F12 · shares: The shares were sold as follows: 2,792 by AM LLC, 17,640 by BV 2014, 1,177 by BV 2014(B), 607 by AM BV2014 and 3,885 by MPM OIF. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.065 to $1.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F14 · ownership.nature: The shares are held as follows: 390,865 by AM LLC, 2,468,451 by BV 2014, 164,642 by BV 2014(B), 84,963 by AM BV2014 and 541,512 by MPM OIF. Read SEC document
November 11, 2025 Filed Nov 13, 2025 00:49 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	35,818	$1.14	$40,832.52	Disclosure SEC source: 0001134657-25-000008 · form4-11132025_121129.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,676,534 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9 · shares: The shares were sold as follows: 3,832 by AM LLC, 24,208 by BV 2014, 1,615 by BV 2014(B), 832 by AM BV2014 and 5,331 by MPM OIF. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.115 to $1.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F11 · ownership.nature: The shares are held as follows: 393,657 by AM LLC, 2,486,091 by BV 2014, 165,819 by BV 2014(B), 85,570 by AM BV2014 and 545,397 by MPM OIF. Read SEC document
November 10, 2025 Filed Nov 13, 2025 00:49 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	31,172	$1.18	$36,782.96	Disclosure SEC source: 0001134657-25-000008 · form4-11132025_121129.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,712,352 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6 · shares: The shares were sold as follows: 3,335 by AM LLC, 21,067 by BV 2014, 1,405 by BV 2014(B), 725 by AM BV2014 and 4,640 by MPM OIF. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.145 to $1.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 397,489 by AM LLC, 2,510,299 by BV 2014, 167,434 by BV 2014(B), 86,402 by AM BV2014 and 550,728 by MPM OIF. Read SEC document
November 07, 2025 Filed Nov 13, 2025 00:49 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	43,950	$1.11	$48,784.50	Disclosure SEC source: 0001134657-25-000008 · form4-11132025_121129.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnotes Disclosed balance after: 3,743,524 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 4,702 by MPM Asset Management LLC ("AM LLC"), 29,704 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,981 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,022 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 6,541 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.075 to $1.188 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The shares are held as follows: 400,824 by AM LLC, 2,531,366 by BV 2014, 168,839 by BV 2014(B), 87,127 by AM BV2014 and 555,368 by MPM OIF. Read SEC document
November 06, 2025 Filed Nov 7, 2025 00:43 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	34,947	$1.21	$42,285.87	Disclosure SEC source: 0001134657-25-000006 · form4-11072025_121126.xml · nonDerivative · entry 3 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 3,787,474 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F8 · shares: The shares were sold as follows: 3,738 by AM LLC, 23,619 by BV 2014, 1,575 by BV 2014(B), 814 by AM BV2014 and 5,201 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.185 to $1.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 405,526 by AM LLC, 2,561,070 by BV 2014, 170,820 by BV 2014(B), 88,149 by AM BV2014 and 561,909 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
November 05, 2025 Filed Nov 7, 2025 00:43 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	30,774	$1.22	$37,544.28	Disclosure SEC source: 0001134657-25-000006 · form4-11072025_121126.xml · nonDerivative · entry 2 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 3,822,421 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F5 · shares: The shares were sold as follows: 3,292 by AM LLC, 20,798 by BV 2014, 1,387 by BV 2014(B), 717 by AM BV2014 and 4,580 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 409,264 by AM LLC, 2,584,689 by BV 2014, 172,395 by BV 2014(B), 88,963 by AM BV2014 and 567,110 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
November 04, 2025 Filed Nov 7, 2025 00:43 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	SaleCommon Stock	90,164	$1.22	$110,000.08	Disclosure SEC source: 0001134657-25-000006 · form4-11072025_121126.xml · nonDerivative · entry 1 EVNIN LUKE · CIK 0001134657 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 3,853,195 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2 · shares: The shares were sold as follows: 9,645 by MPM Asset Management LLC ("AM LLC"), 60,937 by MPM BioVentures 2014, L.P. ("BV 2014"), 4,064 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 2,098 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 13,420 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 412,556 by AM LLC, 2,605,487 by BV 2014, 173,782 by BV 2014(B), 89,680 by AM BV2014 and 571,690 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.